Stage (next event)
Phase 2b/3 (Top-line Data)
Catalyst Info & Data Links
TITLE: TD-1473 (GUT-SELECTIVE JAK INHIBITOR) for Ulcerative colitis - Phase 2b/3 Data
ClinicalTrial.gov (NCT03758443): Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)
WHAT IS THE CATALYST EVENT?
Phase 2b Top-line Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
TD-1473 is an internally-discovered JAK inhibitor that has demonstrated a high affinity for each of the JAK family of enzymes. Importantly, TD-1473 is a gut-selective treatment specifically designed to distribute adequately and predominantly to the tissues of the intestinal tract, treating inflammation in those tissues while minimizing its systemic exposure.
Ulcerative colitis and Crohn's disease, which affect roughly 900,000 and 700,000 patients in the United States, respectively.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post